Glioblastoma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, and others

DelveInsight's, "Glioblastoma Pipeline Insight 2023" report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Glioblastoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Glioblastoma clinical trials studies, Glioblastoma NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma Pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma.
• The leading Glioblastoma Companies include Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience, Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
• Promising Glioblastoma Therapies include TVB2640, Trabedersen, Selinexor, Onfekafuspalfa, AZD1390, YTX7739, and others.
• The Glioblastoma Companies and academics are working to assess challenges and seek opportunities that could influence Glioblastoma R&D. The Glioblastoma pipeline therapies under development are focused on novel approaches to treat/improve Glioblastoma.

To explore more information on the latest breakthroughs in the Glioblastoma Pipeline treatment landscape of the report, click here @ Glioblastoma Pipeline Outlook- https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Overview
Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes that support nerve cells.It can occur at any age, but tends to occur more often in older adults. It can cause worsening headaches, nausea, vomiting and seizures.Glioblastoma, also known as glioblastoma multiforme.

Recent Developmental Activities in the Glioblastoma Treatment Landscape
• On February 2023, Enterome announced a study of phase 1 & 2 clinical trials for Multiple dose of EO240. The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.
• On February 2023, Laminar Pharmaceuticals announced a study of phase 2 & 3 clinical trials for LAM561 and TMZ. The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.

For further information, refer to the detailed Glioblastoma Unmet Needs, Glioblastoma Market Drivers, and Glioblastoma Market Barriers, click here for Glioblastoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Emerging Drugs Profile

Enzastaurin: Denovo BioPharma
DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world's first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive. The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM).

Tofacitinib: Pfizer
Tofacitinib (Xeljanz, Jaquinus) is an immunosuppressant. It is a first-generation, orally bioavailable pan-Jak inhibitor. Tofacitinib was mainly developed for use as an immunosuppressant for organ transplantation and possibly for the treatment of autoimmune diseases. Tofacitinib suppresses the Jak family members at IC50s as follows: Jak1, Jak2, and Jak3, in a cell-free kinase assay. In addition, Tofacitinib effectively suppresses common γ-chain cytokines involving IL-2, IL-4, IL-15 and IL-21. Furthermore, the most common side effects include headaches, upper respiratory infections, diarrhea, and nasopharyngeal inflammation, elevation in low-density lipoprotein and cholesterol levels and reduction in neutrophil numbers. Serious infections including pneumonia, cellulitis and urinary tract infections have been described in patients treated with Tofacitinib. Currently, the drug is in the Phase III stage of its development for the treatment of glioblastoma multiforme.

VT1021: Vigeo Therapeutics
Vigeo's lead asset, VT1021, is a first-in-class dual modulating compound that blocks the CD47 immune checkpoint and activates CD36, which induces apoptosis and increases the M1:M2 macrophage ratio. VT1021 achieves this through stimulation of thrombospondin-1 (Tsp-1). The goal of these dual-modulating effects is conversion of immuno-suppressive, or "cold," tumors that don't respond to immuno-oncology agents, to immuno-stimulated, or "hot," tumors that are potentially more receptive to immuno-oncology agents. Vigeo is developing VT1021 as a therapeutic agent across a range of cancers, with a current focus on solid tumors. Vigeo Therapeutics is advancing VT1021 into a Phase II/III registrational study through the company's collaboration with the Global Coalition for Adaptive Research (GCAR).

Varlilumab: Celldex Therapeutics
Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses and may result in fewer toxicities due to its restricted expression and regulation.

Varlilumab is a potent anti-CD27 agonist that induces activation and proliferation of human T cells when combined with T cell receptor stimulation. Varlilumab has completed a Phase I dose-escalation study, demonstrating potent immunologic activity consistent with its mechanism of action and anti-tumor activity in patients with advanced, refractory disease. No maximum tolerated dose was reached and minimal toxicities were observed. Celldex initiated a broad development program for varlilumab to explore its role as an immune activator in combination with a number of complementary investigational and approved oncology drugs. Currently, the drug is in the Phase II stage of its development for the treatment of glioblastoma multiforme.

Debio 0123: Debiopharm
Debio 0123 is a Wee1 kinase inhibitor. The compound is being developed based on the deepened understanding of the DNA damage response (DDR) of cancer cells. Inhibition of WEE1 prevents cells to arrest or repair DNA damages and force them to prematurely continue through the cell cycle, therefore accumulating unrepaired DNA damages ultimately leading to cell death. The compound is being developed in light of the need to improve cancer patients' treatment response and to overcome treatment resistance to current therapies. Pre-clinical models have shown anti-tumor activity both as a single agent and in combination with carboplatin. The advancement of Debio 0123 into clinical studies will assess the therapeutic results for cancer patients in various tumor types. Currently, the drug is in the Phase I/II stage of its development for the treatment of Glioblastoma.

PRT3645: Prelude Therapeutics
PRT3645 is Prelude's next generation CDK4/6 inhibitor with high tissue distribution and brain penetration. In preclinical studies, PRT3645 treatment resulted in concentration-dependent inhibition of cell proliferation in both glioblastoma (GBM) cell lines and in ER+/HER2- and HER2+ breast cancer lines. In vivo, orally administered PRT3645 was well tolerated and highly efficacious in a dose-dependent manner in orthotopic human breast cancer brain metastasis and GBM models. Currently, the drug is in the Phase I stage of its development for the treatment of Glioblastoma.

Glioblastoma Pipeline Therapeutics Assessment
There are approx. 195+ key companies which are developing the therapies for Glioblastoma. The companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo BioPharma.

Request a sample and discover the recent advances in Glioblastoma Ongoing Clinical Trial Analysis and Medications, click here @ Glioblastoma Treatment Landscape- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Glioblastoma Pipeline Report
• Coverage- Global
• Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience, Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others
• Glioblastoma Pipeline Therapies- TVB2640, Trabedersen, Selinexor, Onfekafuspalfa, AZD1390, YTX7739, and others.
• Glioblastoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Glioblastoma Market Drivers and Glioblastoma Market Barriers, click here @ Glioblastoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Glioblastoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Glioblastoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Trabedersen: Oncotelic Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Selinexor: KaryoPharm Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AZD1390: AstraZeneca
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. YTX7739: Yumanity Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Glioblastoma -Key Companies
21. Glioblastoma -Key Products
22. Glioblastoma - Unmet Needs
23. Glioblastoma - Market Drivers and Barriers
24. Glioblastoma- Future Perspectives and Conclusion
25. Glioblastoma -Analyst Views
26. Glioblastoma -Key Companies
27. Appendix

Got Queries? Find out the related information on Glioblastoma Mergers and acquisitions, Glioblastoma Licensing Activities @ Glioblastoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.